New Jersey S 1650: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

Status: Introduced in the Senate, Referred to Senate Commerce Committee (as of 2020-02-13)

State: New Jersey · Session: 219 · Bill: S 1650

Subjects: HEALTH INSUR, PHARMACEUTIC

Sponsors: Madden, Fred H.

View New Jersey S 1650 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.